Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
ACS Chemical Biology|December 21, 2011
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3GMing Li, Shivender M D Shandilya, Michael A Carpenter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2016
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian CarcinomaBrandon Leonard, Gabriel J Starrett, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian CancerArtur A Serebrenik, Prokopios P Argyris, Matthew C Jarvis, et al.
NPJ Digital Medicine|October 19, 2023
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosisMichael Barnett, Dongang Wang, Heidi Beadnall, et al.
Cell Reports|May 19, 2015
Lineage-Specific Viral Hijacking of Non-canonical E3 Ubiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 ActivityJoshua R Kane, David J Stanley, Judd F Hultquist, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
JCI Insight|May 8, 2019
Keratinocyte growth factor impairs human thymic recovery from lymphopeniaAlasdair J Coles, Laura Azzopardi, Onajite Kousin-Ezewu, et al.
Cancer Research|August 5, 2022
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy CombinationsJesse Boumelha, Sophie de Carné Trécesson, Emily K Law, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Pageof 12